gip tirzepatide (LY3298176) Putative mechanism(s) of action of

The drug is currently an investigational molecule and does not have regulatory approval

However, a new study published in the journal eClinical Medicine reports that most people regain about 60 % of the weight lost within a year of stopping treatment

Interaction with melatonin : It might increase the risk of bleeding

However, some individuals may remain on a lower dose longer if they experience side effects or achieve satisfactory results without increasing the dosage

It could be subtle hormonal shifts that TRT and medications like Semaglutide can correct

Liver disease may be one of the next major frontiers, with growing evidence that incretin-based therapies can improve MASH resolution and fibrosis-related endpoints